Lakewood-Amedex Biotherapeutics PEG Ratio

Lakewood-Amedex Biotherapeutics (LABT) currently reports a PEG ratio of -0.02. That is below the Healthcare sector average of 11.77. Use the charts on this page to explore Lakewood-Amedex Biotherapeutics's PEG ratio history and peer comparisons.

Lakewood-Amedex Biotherapeutics's PEG ratio of -0.02 is lower than the Healthcare sector average of 11.77. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Lakewood-Amedex Biotherapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.02, LABT can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -0.02, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.77. From there, open related valuation or income-statement pages for Lakewood-Amedex Biotherapeutics, and consider following LABT for alerts when major investors trade the stock.

Lakewood-Amedex Biotherapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows -0.02 versus a sector average near 11.77. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LABT with unrelated industries.